RUNX1T1 and mediastinal yolk sac tumor: This study intended to investigate the effect of neocryptolepine analog (APAN) alone or/and combined with Etoposide (ETO) as co-treatment for Ehrlich solid tumor (EST)-caused hepatic injury in female mice and its synergism and ability to use with established chemotherapy, which prompted our interest to select topoisomerase II as an interesting target for molecular docking to support the biological results, as ETO action is based on the inhibition of topoisomerase II.